At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 236 enrolled
Drug / intervention
AGN-223575 ophthalmic solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease
In Brief
A Phase 2 clinical trial evaluating AGN-223575 ophthalmic solution and AGN-223575 vehicle ophthalmic solution for Dry Eye Syndromes. Completed, enrolled 236 participants across 28 sites.
Detailed Summary
This study will evaluate the safety, efficacy, tolerability, and systemic pharmacokinetics of 3 different doses of topical ophthalmic AGN-223575 suspension compared to AGN-223575 vehicle in patients with dry eye disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Syndromes
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartJun 2015
Primary CompletionJan 2016
TodayJul 2026
First PostedMay 6, 2015
Enrollment StartJun 1, 2015
Primary CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 11.2 years ago
Interventions
AGN-223575 ophthalmic solutiondrug
AGN-223575 ophthalmic solution once or twice daily
AGN-223575 vehicle ophthalmic solutiondrug
Vehicle to AGN22375 ophthalmic solution once or twice daily.